In a major policy overhaul to ensure safe and standardized movement of medicines, the Indian government has rolled out new pharma transport norms 2025 that take effect from August. These rules are aimed at strengthening the quality, safety, and compliance of drug delivery via road networks across India. The pharmaceutical supply chain plays a critical … Read more
The Pharma Internship Programs 2025 are opening new doors for students pursuing B.Pharm and M.Pharm degrees in India. These hands-on learning opportunities are giving young professionals a chance to gain real-time exposure in pharmaceutical manufacturing, R&D, clinical trials, regulatory affairs, and digital pharma technologies. With increasing emphasis on practical skills in the industry, top pharma … Read more
The Pharma Pricing Policy Amendment 2025 has officially brought a new wave of price control and accessibility in India’s healthcare system. With updated price capping mechanisms and broader coverage of essential drugs, the National Pharmaceutical Pricing Authority (NPPA) has taken strong steps to regulate medicine costs in 2025. This year’s amendment ensures more transparency and … Read more
The Government of India has updated the Bulk Drug Production Linked Incentive Scheme 2025, providing revised subsidies and guidelines for the manufacturing of critical Active Pharmaceutical Ingredients (APIs) within the country. This initiative supports the “Atmanirbhar Bharat” mission by reducing import dependency and boosting local pharmaceutical manufacturing. With the 2025 update, the scheme offers more … Read more
The Pharma Manufacturing Hubs 2025 initiative is transforming India’s pharmaceutical production landscape with state-of-the-art industrial clusters across the country. Under the Atmanirbhar Bharat and Pharma Vision 2047 programmes, the Government of India has announced the operational rollout of several new pharmaceutical manufacturing hubs aimed at boosting exports, generating employment, and strengthening drug security. These dedicated … Read more
The Indian Pharma Bulk Drug Import 2025 landscape reveals some critical trends in sourcing, cost dynamics, and dependency on global suppliers. Despite India being a global leader in generic drug manufacturing, a significant portion of Active Pharmaceutical Ingredients (APIs) and bulk drugs are still imported—especially from countries like China. In 2025, bulk drug imports have … Read more
The Government of India has officially launched the Pharma Innovation Fund India 2025, allocating ₹1500 crore to fuel pharmaceutical research and development across the country. This strategic initiative is aimed at boosting India’s self-reliance in drug discovery, biotechnology, and formulation sciences. As a part of the Department of Pharmaceuticals’ Vision 2047 roadmap, this fund is … Read more
The Government of India has officially announced a significant change in API Import Duty India 2025, effective from August. This move is a part of the larger policy to promote domestic manufacturing of Active Pharmaceutical Ingredients (APIs) under the Atmanirbhar Bharat initiative. The updated duty structure introduces increased import tariffs on over 40 high-demand APIs, … Read more